about
HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophySAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's diseaseHDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegenerationHDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivoGenetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's diseaseEarly transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy.The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model.Skeletal muscle pathology in Huntington's diseaseDysfunction of the CNS-heart axis in mouse models of Huntington's disease.Update on Huntington's disease: advances in care and emerging therapeutic options.Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice.HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievementsAn impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington's disease related cardiomyopathy.Huntington's disease is a multi-system disorder.A shared mechanism of muscle wasting in cancer and Huntington's disease.VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development.Identification of 6-furfuryladenine (kinetin) in human urine
P50
Q27311425-F7000F9E-221A-4384-AD2A-A75308232C39Q27312323-C8C14DAE-2D97-4937-91DB-973E6AC6BE5BQ27316520-4337A630-0731-4823-B528-3F1836D96A77Q28535389-4D496DA5-261E-416A-999D-788DA00B3A19Q33457171-A73F0D84-7EF8-49F7-A0D7-8F41C22A32F2Q33853732-7641E4BA-CC12-46A0-9325-3452EC80EE5DQ34277801-B4449519-B81E-4EFA-AB28-E107D8978173Q34292092-E4CC2DE9-8AFC-49CA-BB23-956D95DE76D4Q35220835-B51F470A-2D77-493E-8289-78721DA993A1Q35540552-0A1FA85F-EC2C-4936-AAD5-4B90B2B79DD0Q37237181-A8F2E9AA-58F8-46E1-9D1A-FE76AB0C943CQ38373328-F0967D26-AF21-4E13-B9F5-D82D61D70544Q38827109-84AFA25F-5A5C-4180-83A5-3195070F44A1Q41597422-2BB577FA-2BA2-40F9-8FF4-FEE2843BA87AQ43131306-F127D0CF-125D-48FF-A21D-0D687B3BDF3EQ51943350-A37190E6-ED8A-496E-AC3E-32A5C5A41C01Q73287051-9B1AD809-0CBB-40E6-9B03-9BBED5A7AABD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michal Mielcarek
@ast
Michal Mielcarek
@en
Michal Mielcarek
@es
Michal Mielcarek
@nl
type
label
Michal Mielcarek
@ast
Michal Mielcarek
@en
Michal Mielcarek
@es
Michal Mielcarek
@nl
prefLabel
Michal Mielcarek
@ast
Michal Mielcarek
@en
Michal Mielcarek
@es
Michal Mielcarek
@nl
P106
P1153
7003373406
P31
P496
0000-0002-9874-6753